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One hallmark of cancer is the degradation of the extracellular matrix (ECM), which is caused by proteinases. In oral cancers, matrix
metalloproteinases (MMPs), especially MMP-9, are associated with this degradation. MMPs break down the ECM allowing cancer
to spread; they also release various factors from their cryptic sites, including cytokines. ese factors modulate cell behavior and
enhance cancer progression by regulating angiogenesis, migration, proliferation, and invasion.e development of earlymetastases
is typical for oral cancer, and increasedMMP-9 expression is associated with a poor disease prognosis. However, many studies fail to
relateMMP-9 expression with metastasis formation. Contrary to earlier models, recent studies show thatMMP-9 plays a protective
role in oral cancers. erefore, the role of MMP-9 is complicated and may �uctuate throughout the diﬀerent types and stages of
oral cancers.
1. Introduction
Oral cancer is one of the ten most common cancers world-
wide. Nearly 3% of all cancer cases are oral cancers; they are
more common in men than in women; and two-thirds of
oral cancer cases occur in developing countries [1, 2]. One
important hallmark of cancer progression is the degradation
of the extracellular matrix (ECM), which allows cancer cells
to invade the surrounding tissue. Matrix metalloproteinases
(MMPs) are zinc-dependent endopeptidases that eﬃciently
degrade the components of the ECM and basement mem-
branes (BM). MMPs also release cytokines, chemokines, and
growth factors from their proforms or their cryptic sites
[3–6]. To date, at least 24 distinct MMP genes have been
identi�ed in humans. MMPs are classi�ed according to their
substrate speci�cities: gelatinases, collagenases, matrilysins,
and stromelysins. e structures of all MMPs include an N-
terminal signal peptide that directs the protein to either the
plasma membrane insertion or to the secretory pathway; its
prodomain confers its latency, and its catalytic domain has
a zinc atom in its active site. MMPs are either anchored
in the membrane or secreted, primarily as latent proforms
that require activation before becoming catalytically com-
petent [7–9]. Two diﬀerent soluble gelatinases have been
identi�ed: gelatinase A, 72 kDa (MMP-2), and gelatinase B,
92 kDa (MMP-9). Both contain a collagen-binding domain
within their catalytic domain, distinguishing them from
other MMPs. A more detailed structure of these enzymes is
described in a review by Björklund and Koivunen [10].
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T 1: Synthetic MMP-9 inhibitors.
Name Type of drug Speci�ty of the inhibition Reference
Batimastat Peptidomimetic MMP-1, -2, -3, -7, -9 [40]
Marimastat Peptidomimetic Broad spectrum [41]
CTTHWGFTLC Peptidomimetic MMP-2, -9 [38]
CGYGRFSPPC Peptidomimetic MMP-2, -9 [42]
CRVYGPYLLC Peptidomimetic MMP-2, -9 [42]
ABT-518 Peptidomimetic MMP-2, -9 [43]
GRENYHGCTTHWGFTLC Peptidomimetic MMP-2, -9 [39]
Ilomastat Peptidomimetic Broad spectrum [44]
Tanovastat Nonpeptidomimetic MMP-2, -3, -9 [45]
Prinovastat Nonpeptidomimetic MMP-2, -3, -7, -9, -13 [46]
BMS-275291 Nonpeptidomimetic MMP-2, -9 [47]
Metastat (COL-3) Chemically modi�ed tetracycline MMP-1, -2, -8, -9, -13 [48]
CMT-3 Chemically modi�ed tetracycline MMP-8, -9, -MT1-MMP [49]
Doxycycline Chemically modi�ed tetracycline MMP-1, -2, -3, -8, -9, -10, -13 [50]
SB-3CT Reform proenzyme structure MMP-2, -9 [51]
Bisphosphonates Analogues of inorganic pyrophosphate MMP-1, -2, -7, -9, MT1-, MT2-MMP [52]
Chlorhexidine Bisbiguanide antiseptic MMP-2, -8, -9 [53]
Letrozole Nonsteroidal inhibitor of aromatase MMP-2, -9 [54]
PCK 3145 Synthetic peptide based on PSP94 MMP-9 [55]
2. Activation of MMP-9
Typically, gelatinases are secreted as inactive zymogens that
become activated extracellularly. e most relevant natural
activators of proMMP-9 are unknown, but proMMP is
activated through a few diﬀerent mechanisms, including
proteolytic activation, where the prodomain is cleaved
yielding an active enzyme. Latent MMP-9 can be activated
by MMP-3, which cleaves proMMP-9 at multiple sites: the
�rst cleavage site is Glu59-Met60; the second is Arg106-Phe107
[11]. In contrast, MMP-26 activates MMP-9 by cleaving at
Ala93-Met94 [12]. Previous studies have also demonstrated
that enterokinase, a membrane-bound serine protease,
cleaves proMMP-9 at Lys65-Ser66 [13] and that trypsin-2
activates proMMP-9 at very low molar ratios, 1 : 1000. e
peptide bond can also be cleaved at Arg87-Phe88 [14]. Other
known proteolytic activators are plasmin, chymotrypsin-
like proteinase, MMP-2, MMP-7, MMP-10, and MMP-13
[15–20]. ere are other identi�ed activation mechanisms
for MMP-9: oxidation by reactive oxygen species, S-
nitrosylation, and allosteric activation, which occurs when
proMMP-9 is bound to either a gelatin or type IV collagen
[21–23]. In an invasive tongue squamous cell carcinoma
cell line (HSC-3), MMP-9 is colocalized with trypsin-2 in
intracellular vesicles [13]. is intracellular activation may
be an alternative activation mechanism for proMMPs in oral
cancers. Similar intracellular vesicle transports for MMP-
9 are also found in melanoma cells and in ovarian cancer
ascites [24, 25]. In oral squamous cell carcinoma (OSCC), the
activation level ofMMP-9may be associatedwith a shortened
disease-free survival and a high metastatic frequency [26].
3. Inhibitors of MMP-9
Tissue inhibitors of metalloproteinases (TIMPs) are speci�c
endogenous inhibitors of MMPs, which bind MMPs in a 1 : 1
stoichiometry. Four diﬀerent TIMPs have been identi�ed:
TIMP-1, TIMP-2, TIMP-3, and TIMP-4 [27]; they all inhibit
MMP-9 in vitro [28–31]. e role of TIMPs in OSCC is well-
studied and is the focus of a recent review byGarćia et al. [32].
Aer the role of MMPs in cancer invasion and metastasis
formation was recognized, researchers began developing
synthetic inhibitors. e �rst generation of peptidomimetic
MMPs, batimastat (BB94) and ilomastat (GM-6001), mim-
icked the structure of collagen and reversibly bound the active
site ofMMPs to inhibitMMP activity [33, 34]. Next,Marima-
stat (BB-2516), a second generation of MMP inhibitors, was
developed. However, all of these broad-spectrum inhibitors
failed in clinical trials due to their side eﬀects and their
lack of eﬃcacy [35–37], which led to the development of
more selective matrix metalloproteinase inhibitors (MMPIs).
We developed the �rst gelatinase-speci�c MMPI CTTH-
WGFTLC peptide, which inhibited the invasion of ovarian
carcinoma, breast carcinoma, �brosarcoma, Kaposi�s sar-
coma, and melanoma cell lines, in vitro; it also increased
the survival of human tumor xenogras [38]. Since then,
we have developed a cyclic gelatinase-speci�c inhibitor
GRENYHGCTTHWGFTLC peptide, which inhibits MMP-9
activation and activity, the growth of human tongue cancer
cell xenogras, and angiogenesis in nude mice [39]. e
synthetic MMPIs that inhibit MMP-9 are listed in Table 1.
4. MMP-9 in the Oral Microenvironment
In addition to carcinoma cells, cancers consist of tumor-asso-
ciated stromal cells, which include �broblasts, endothelial
cells, leukocytes, macrophages, nerve cells, and adipocytes.
During cancer progression, the cancer cells crosstalk with
stromal components and their interactions are partially
mediated by transmembrane receptors, which are expressed
on cancer cells and stromal cells. Tumor-associated cells
promote angiogenesis, in�ammation, invasion, and ECM
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modeling through cell-cell contact and the production of
growth factors, hormones, cytokines, and proteinases such
as MMPs [56–58]. In OSCC tumors, MMP-9 is expressed in
carcinoma and in�ammatory cells around carcinoma islands.
Meanwhile, MMP-2 is mainly found in carcinoma-associated
�broblasts (CAFs) [59, 60]. In an oral squamous cell car-
cinoma cell line SCC-25, CAFs increase the expression of
MMP-9, in vitro, which is thought to occur via a �bronectin-
integrin 𝛼𝛼v𝛽𝛽6 pathway [61]. In the aggressive human tongue
squamous cell carcinoma cell line HSC-3, MMP-2 was only
found in its latent form, whereas MMP-9 was found in its
active form [13]. MMP-9
′
s eﬀect during HSC-3 cell line
invasion was studied in a human organotypic model based
on myoma tissue [62], which contains �broblasts, smooth
muscle cells, lymphocytes, macrophages, endothelial cells,
and MMP-2, but not MMP-9 [62]. erefore, this model is
a better predictor of the in vivo tumor microenvironment
compared with the commonly used rat tail-derived type I
collagen and/or the mouse EHS sarcoma-derived Matrigel
invasion assay. In the myoma organotypic invasion assay,
aer inhibiting gelatinase activity in HSC-3 cells using a
speci�c gelatinase inhibitor CTTHWGFTLC [38], the tumor
cells were surprisingly more invasive than in the control
group (unpublished data). Mice bearing HSC-3 xenogra
tumors treated with the gelatinase inhibitor CTTHWGFTLC
had smaller primary tumors in vivo than the control group
[39], but the inhibition of gelatinases did not aﬀect local
invasion or metastasis formation [63]. e ability of cancer
cells to change their migration under certain circumstances
from proteolytic to non-proteolytic, amoeboid type during
protease-inhibitor treatment helps to explain the OSCC
behaviors we observed. us, these cells change their shape
and adapt to squeeze through tissue gaps without degrading
the ECM [64]. MMP-9 may not be the only, or even the
most important, proteolytic enzyme in the OSCC invasion
process, but it may be important for indirect cell signaling
by controlling the bioavailability and bioactivity of molecules
that target speci�c receptors, which regulate cell growth,
migration, in�ammation, and angiogenesis [65–69].
5. The Role of MMP-9 in OSCC Invasion
andMetastasis
MMP-9 is associated with the aggressive nature of many can-
cers, including OSCC [81–84], and this aggressive nature was
thought to cause type IV collagen degradation, a main com-
ponent of basement membranes [85]. To date, the spectrum
of MMP-9 matrix substrates has signi�cantly increased, and
aside from substrates, which originate in the matrix, MMP-
9 has other bioactive substrates that independently modulate
carcinogenesis, such as the pro-transforming growth factor-
𝛽𝛽1 (TGF-𝛽𝛽1) and the pro-tumor necrosis factor-𝛼𝛼 (TNF-
𝛼𝛼) [10, 86, 87]. MMP-9 has traditionally been associated
with the aggressive nature of OSCC. However, in spite
of increased MMP-9 expression levels, many researchers
have presented contradictory results [70–72] (Table 2). For
example, Guttman et al. [73] did not �nd a correlation
between MMP-9 expression and the size of the primary
tumor or the neck metastasis in tongue SCC patients. Mean-
while, another study reported that high levels of MMP-9
expression in OSCC patients were correlated with regional
lymph node and/or distant metastases and a poor prognosis
[74]. In addition, De Vicente et al. [78] showed that MMP-
9 expression was not associated with clinical variables, such
as tumor stage or recurrence rate. In a study conducted by
Ikebe et al., gelatinolytic activity and increased expression
of both MMP-2 and MMP-9 in OSCC tumors were related
to the invasiveness, but not to the metastatic potential of
OSCC tumors [75]. Finally, Kato and co-workers [76] showed
that, although MMP-9 expression was high in OSCCs, the
activated form:proform ratio was very low, while activated
MMP-2s were elevated and associated with advanced stages
of disease. ese �ndings suggest that MMP-9 may not be
a universal cancer progression promotion factor in OSCCs;
instead, it may have �uctuating roles.
6. MMP-9 in theModulation of
Can�e�-Related In�a��ation
Chronic in�ammation is associated with epithelial cancers,
and it diﬀers from normal in�ammation because it is not
self-limiting. Cancer cells produce diﬀerent cytokines that
attract innate immune cells, such as mast cells, granulo-
cytes, and macrophages. ese innate immune cells then
secrete interleukins, chemokines, reactive oxygen species,
and MMPs that modulate angiogenesis, cell proliferation,
tumor growth, and invasion [88–90]. In OSCCs, the level
of a multifunctional cytokine, transforming growth factor-
𝛽𝛽1, is upregulated, which leads to the enhanced expression
of snail. Snail is a transcription factor that increases MMP-9
expression and triggers an epithelial-mesenchymal transition
(EMT); then, carcinoma cells change their morphology,
reduce their intercellular and cell-matrix adhesions, and
increase their motility [91, 92]. Interestingly, the inactive
form of TGF-𝛽𝛽1 is activated by MMP-9 [93]. Many other
cytokines are also substrates for MMP-9, including TNF-𝛼𝛼,
CXCL1, CXCL4, CXCL7, CXCL8, and interleukin-1𝛽𝛽 [65–
67]. Interleukin-1𝛽𝛽 is secreted by tumor cells and induces
the expression of lipocalin 2 [94, 95]. e plasma levels of
lipocalin 2, MMP-9 and the lipocalin 2/MMP-9 complex are
associated with more advanced clinical stages and/or tumor
sizes in OSCC patients. Interestingly, MMP-9 levels are not
correlated with either lymph nodes or distant metastases
[77]. Chemokine CXCL8 can induce the release of MMP-
9 from tertiary neutrophil granules, and increased CXCL8
expression is associated with OSCC. e CXCL8 expressed
in tumor cells is also secreted by OSCC cell lines, and CXCL8
mRNA expression is enhanced by the addition of TNF-𝛼𝛼 and
IL- 1𝛽𝛽. CXCL8 fromOSCC cell lines increases cell migration,
induces invasion, and increases the expression of MMP-7.
However, it does not have an eﬀect on MMP-9 expression.
erefore, CXCL8-induced expression of MMP-9 may be
cell-type speci�c [96–98]. e chemokine receptor, CXCR4,
modulates the invasion of OSCCs by regulating MMP-9
expression. In patients, this expression correlates with lymph
node metastasis and MMP-9 expression [99, 100]. Cyclo-
oxygenase (COX)-2 is an enzyme that converts arachidonic
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T 2: MMP-9 expression in oral cancer.
MMP-9
expression Sample type
Lymph node
metastasis Outcome
MMP-9
activity Method
Number of
cases References
High Tissue Yes ∗ ∗ Immunohistochemistry 96 [70]
Yes Tissue Yes ∗ ∗ Immunohistochemistry 61 [71]
High Tissue ∗ Shortened diseasesurvival High Gelatin zymography, 44 [72]
Yes Tissue No nc ∗ Immunohistochemistry 23 [73]
High Tissue Yes Poor ∗ Immunohistochemistry 53 [74]
High Tissue No ∗ High
Gelatin zymography,
immunohistochemistry,
western blot
57 [75]
High Tissue ∗ ∗ Low
Immunohistochemistry,
gelatin zymography, 31 [76]
High Plasma No ∗ ∗ ELISA 195 [77]
Yes Tissue No nc ∗ Immunohistochemistry 68 [78]
High Tissue ∗ Better survival ∗ Immunohistochemistry 12 [79]
High Tissue Yes Shortened diseasesurvival
∗ Immunohistochemistry 48 [80]
∗not studied, nc: no correlation.
acid into pro-in�ammatory prostanoids. COX-2 has been
implicated in carcinogenesis and its mRNA expression is
nearly 150-fold greater in head and neck squamous cell
carcinomas compared with normal oral mucosa. Using a
selective COX-2 inhibitor decreases MMP-9 and MMP-2
expression and suppresses the proliferation and invasion of
OSCCs [101, 102]. In fact, MMP-9 has many links to the
cancer-related in�ammation observed in OSCCs, but MMP-
9′s speci�c role in this process remains unclear.
7. MMP-9 in the Regulation of Angiogenesis
Low oxygen levels, or hypoxia, are typical in solid tumors that
grow 1-2mm3 without vascularization. Angiogenesis, the
formation of new blood vessels, is required to bring nutrition
and oxygen to cells, remove metabolic waste, and support
larger tumor growth. Not only is angiogenesis associated
with tumor growth, it is also related to the development
of metastases in OSCCs [103–107]. is process is ini-
tiated by vascular endothelial growth factor (VEGF), an
angiogenic cytokine. e eﬀect of VEGF is mediated by
vascular endothelial growth factor receptors. e hypoxic
conditions stabilize hypoxia-inducible factors (HIFs) that
bind to the VEGF promoter, which causes upregulation of
VEGF and increases the expression of VEGFR-receptor-1 in
endothelial cells, cancer cells and tumor-associated cells, such
as macrophages [105, 108–111]. In OSCCs, overexpression
of HIF-1𝛼𝛼 is associated with a poor patient outcome [112].
Increased tumor hypoxia is also associated with increased
MMP-2 and MMP-9 activity [113].
e regulation of angiogenesis is a very delicate balance
between pro- and antiangiogenic factors, and it seems that
MMP-9 plays a dual role in this process. It can act as a
proangiogenic factor via VEGF regulation; as Hiratsuka et
al. [114] demonstrated, primary tumors in premetastatic
lungs induce MMP-9 expression in a VEGFR-1-dependent
manner, which enhances the invasion of cancer cells and
facilitates metastasis. MMP-9 also triggers the angiogenic
switch by releasing VEGF [87]. MMP-9 and VEGF are
expressed during invasive OSCCs of the tongue and in
metastatic tumors that tend to express higher levels of
VEGF and MMP-9, than nonmetastatic tumors [115]. In
another study, increased VEGF expression was associated
with a poor prognosis in OSCC patients, whereas MMP-9
expression levels had no correlation with patient outcomes
[116]. is can be explained by the antiangiogenic role
of MMP-9, which causes cleavage of type XVIII collagen,
and leads to the release of endostatin, a potent inhibitor
of angiogenesis and endothelial cell migration [68, 69].
OSCC primary tumors that do not metastasize have high
endostatin levels compared with primary tumors that are
associated with multiple metastatic lymph nodes. Full-length
collagen XVIII expression levels are decreased in aggressive
tumors [117]. Based on our study [118], collagen XVIII
was expressed in mild oral epithelial dysplasias but was
absent in the invasive fronts of OSCCs. Although MMP-9
expression was observed in these same samples, there was no
correlation between MMP-9 and the stage of disease. Homer
et al. [119] reported that in head and neck squamous cell
carcinoma, the plasma levels of endostatinmay predict tumor
recurrence. Collagen XVIII and VEGF are both expressed
at the same time in OSCCs, which further demonstrates
that modulation of angiogenesis requires a delicate balance
between angiogenic inhibitors and stimulators [109]. More-
over, we have demonstrated that endostatin also directly
inhibits the invasion and intravasation of a human tongue
SCC cell line and blocks the activity of proMMP-9, suggesting
a feedback loop for MMP-9 regulation [120]. When mice
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F 1: Eﬀect of MMP-9 on angiogenesis in oral cancer. MMP-9 inhibits angiogenesis by releasing antiangiogenic factors from their
precursors. MMP-9 enhances angiogenesis by releasing and activating VEGF from extracellular proteoglycans.
bearing nasopharyngeal carcinoma tumors were treated with
endostar (recombinant endostatin), the treatment led to a
signi�cant decrease in MMP-9 and VEGF expression levels
and normalized the tumor vasculature [121]. Endostatin
was not the only cryptic angiogenesis inhibitor liberated
by MMP-9. Angiostatin, a fragment of plasminogen, also
inhibits endothelial cell proliferation [86, 122]. Pozzi et
al. [123] proved that decreased MMP-9 plasma levels in
tumor-bearing mice also decreases angiostatin levels, which
increases tumor vascularization and growth.Matsumoto et al.
[124] observed that angiostatin-overexpressing SCC tumors
in mice grew slower than the control tumors. Aside from
endostatin and angiostatin production, MMP-9 is also asso-
ciated with the proteolytic degradation of type IV collagen,
which produces an angiogenesis inhibitor, tumstatin [125,
126]. ese �ndings suggest that in cancer angiogenesis
the variations in spatial and temporal MMP-9 expression
may switch between two roles: from a proangiogenic to an
antiangiogenic molecule (Figure 1).
8. Eﬀect of Genetic and Environmental Factors
on the Expression of MMP-9
e development and progression of OSCCs are a result
of interactions between accumulating genetic alterations
and environmental factors, such as alcohol, tobacco, viral
infection, or chronic in�ammation [127]. Despite newer
cancer treatments, approximately 50% of patients die within
5 years of diagnosis [128]. is can be partially explained
by the theory of oral �eld cancerization: an oral mucosa
exposed to carcinogens, such as alcohol, causes multiple
genetic abnormalities in the entire epithelium and increases
the risk of developing several dysplastic lesions [129]. Poly-
morphisms in the MMP9 gene allele are associated with an
increased risk of developing the initial stages of oral cancer
among patients without a family history of cancer and high
smoking and/or alcohol use [130].MMP-9 expression did not
correlate with age, gender, tumor location, or smoking habits,
whereas an association with tumor grade diﬀerentiation and
alcohol consumption was observed [78]. MMP-9 was not
expressed in the normal oral mucosa or dysplasia, whereas
in situ carcinomas were weakly detectable. In OSCC, it was
expressed in the same areas where collagen (IV) chain loss
was observed at the invasive fronts, whereas in other studies,
its overexpression was detected in 85% of oral dysplasias and
in all of the oral cancer samples. e mRNA levels of MMP-
9 were higher in oral dysplasia that progressed to oral SCC
[131, 132]. Ogbureke et al. 2012 [133] proposed that MMP-9
expression at histologically negative surgical margins could
predict OSCC recurrence. Interestingly, MMP-9 was absent
from the margins of tumors ≤4 cm and only 10% of tumors
without later node metastasis expressed it. MMP-9 expres-
sion alternates between diﬀerent stages of malignant trans-
formations. Diﬀerent clinicopathological variables in OSCCs
can partially be explained by viral infections in epithelial cells.
e human papilloma virus (HPV) is associated withOSCCs,
especially type 16. HPV16 transgenic mice, HPV16/MMP-
9 +/+ and HPV16/MMP-9 +/− develop a similar incidence
of SCC aer 12 months of age, whereas HPV16/MMP-9 −/−
mice have fewer tumors, but these tumors were more poorly
diﬀerentiated than those in the other groups. e expression
of HPV16 oncoproteins in human keratinocytes induced
the upregulation of MMP-9 activity. At the same time,
two natural MMP inhibitors were downregulated. One of
them was the reversion-inducing cysteine-rich protein with
Kazal motifs (RECK), which aﬀects transcription, synthesis,
activation, and the activity of MMPs; the other was TIMP-2
[134–136]. HPV16 infection may be one mechanism behind
the contradictory expression of MMP-9 in OSCC patients;
however, further studies are necessary to understand its
signi�cance.
9. Methods for MMP-9 Investigation in
Oral Cancer
e most commonly used immunohistological analyses of
MMP-9 expression can be misleading because most antibod-
ies do not distinguish between the pro- and active forms
of the protein. e total amount of protein expression does
not necessarily mean that the enzyme is in an active form
[137]. Gelatin zymography or in situ zymography [138, 139]
are better methods to evaluate the level of gelatinase activity
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MMP-9
Processing of cytokines, cell surface and
cell adhesion proteins, growth factors
Proteolytic processing of ECM
Anti-angiogenesis Angiogenesis Invasion,
tumor growth,
metastasis
Inflammation EMT
F 2: Schematic picture of the events that are modulated by MMP-9 in oral cancer. Proteolytic degradation of ECM components
(including types III, IV, and V collagens, as well as gelatin) by MMP-9 facilitates carcinoma cell invasion and leads to the release of growth
factors, such as VEGF, that enhance angiogenesis and tumor progression. At the same time anti-antiangiogenic endostatin, angiostatin, and
tumstatin are released. Processing of proin�ammatory chemokines (C�CL1, -4, -8, -9, -11, -12), proforms of cytokines (proTNF-𝛼𝛼, proIL-
1𝛽𝛽), cell adhesion proteins such as intercellular adhesion molecule-1 triggers an in�ammatory reaction and modulates transcription factors
leading to an epithelial-to-mesenchymal transition and enhanced carcinogenesis.
and would have provided more information in the studies
referred to here (Table 2) [139]. Many other techniques can
investigate the presence, amount and function ofMMP-9. For
example, in situ hybridization could de�ne the location and
number of cells that expressMMP-9mRNA in tissue sections,
whereas the polymerase chain reaction (PCR) could detect
the presence and amount of mRNA in tissues or cell extracts
[140, 141]. More speci�c intracellular localization of MMP-
9 could easily be achieved using confocal laser scanning
microscopy, which enables a 3-dimensional de�nition of pro-
tein localization [13]. Enzyme-linked immunosorbent assays
(ELISAs) could be used to determine the concentration of
MMP-9 protein in serum and plasma samples; based on these
studies, MMP-9 is a systemic biomarker that monitors the
eﬀectiveness of OSCC treatment [112, 141, 142]. Diﬀerent
blotting methods, Western, Northern, and Southern, reveal
the expression of protein, RNA or DNA, respectively, in
various samples [75, 143]. MMPIs, transfected cell lines, and
knock-out animal models give more functional data about
MMP-9 [144, 145]. Most likely, the variety of methodologies
and the low sample sizes explain the high variation observed
among the previous OSCC results. erefore, more studies
with larger well-documented clinicalmaterials, using delicate
methods, are necessary to determine the impact ofMMP-9 in
OSCC.
10. Conclusions
Generally MMP-9 has been associated with aggressive head
and neck cancers, but novel studies have shown that it acts as
a protective molecule during carcinogenesis and metastasis.
For example, in salivary gland myoepithelial carcinoma,
MMP-9 expression predicts a better overall survival, and in
regional metastases of head and neck cancers, MMP9 gene
expression was decreased [79, 146]. Similarly, the expression
of MMP-9 is associated with a better outcome in breast-
and colitis-associated carcinomas [147, 148]. Additionally, in
oral cancer the role of MMP-9 was purely associated with
the degradation of the ECM, which led to the enhancement
of carcinoma cell invasion. However, the philosophy of
oral carcinoma progression has become signi�cantly more
complicated; now, MMP-9 is known as a multifunctional
modulator that is involved in very complex cell-signaling
cascades (Figure 2). erefore, in the case of MMP-9, one
reason for the obvious failures of broad-spectrumand speci�c
MMPIs in cancer treatment might be due to its �uctuating
role in cancer, which not only aﬀects carcinoma cells but also
other cell populations. e tumor microenvironment matrix
expresses and sequestersMMP-9. Taken together, our current
knowledge of MMP-9 has been extended; it can act as either
a carcinoma protector or promoter depending on the speci�c
situation, which is related to patient characteristics, including
the stage, grade, and location of the tumor.
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